Management of Ubrelvy-Refractory Migraine
If ubrogepant (Ubrelvy) fails to control your patient's migraine attacks, switch to combination therapy with a triptan plus an NSAID (or acetaminophen if NSAIDs are contraindicated), as this represents the most effective first-line treatment according to the 2025 American College of Physicians guidelines 1.
Treatment Algorithm for Ubrelvy Failure
Step 1: Verify Adequate Dosing
Before switching medications, confirm your patient is using ubrogepant correctly:
- Correct dose: 50-100 mg at migraine onset 2
- Timing: Taking medication early in the attack, not waiting until pain is severe
- Frequency: Not exceeding 8 migraines treated per 30 days (safety limit) 2
- Second dose option: A second dose can be taken ≥2 hours after the first, with maximum 200 mg per 24 hours 2
Step 2: Switch to Triptan + NSAID Combination
The 2025 ACP guideline explicitly positions gepants (including ubrogepant) as options for patients who have already failed triptan-NSAID combination therapy 1. Since your patient is failing ubrogepant, the logical next step is to move to the more effective combination:
- Choose a triptan: almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, or zolmitriptan
- Combine with NSAID: aspirin, celecoxib, diclofenac, ibuprofen, or naproxen
- Alternative if NSAIDs contraindicated: Triptan + acetaminophen 1
Key point: Patients who fail one triptan may respond to another within the same class, so trial multiple triptans if the first is ineffective 1.
Step 3: Consider Alternative Gepants or Other Agents
If triptan-NSAID combination fails or is contraindicated:
- Try a different gepant: Rimegepant or zavegepant may work when ubrogepant doesn't, as individual response varies 1
- Dihydroergotamine: Consider for refractory cases 1
- Lasmiditan (ditan): Reserve for patients who fail all other treatments, though note driving restrictions and higher adverse effect burden (number needed to harm = 4) 1, 3
Step 4: Address Preventive Therapy
Critical consideration: If acute treatments are failing or the patient requires frequent dosing, preventive medication is warranted 1. The guideline explicitly states that frequent episodic migraine or inadequate acute treatment response indicates need for prevention 1.
Important Caveats and Pitfalls
Medication Overuse Headache Risk
Monitor for medication overuse headache, defined as:
- Headache ≥15 days/month for ≥3 months
- Gepants threshold: ≥10 days/month (same as triptans)
- NSAIDs threshold: ≥15 days/month 1
What NOT to Use
Avoid opioids and butalbital for acute migraine treatment 1. These are explicitly contraindicated in the guidelines.
Special Situations
- Severe nausea/vomiting: Use nonoral triptan formulation (nasal spray, subcutaneous injection) plus antiemetic 1
- Pregnancy/lactation: Discuss risks of all pharmacologic treatments; ubrogepant may cause fetal harm based on animal data 2
- Cardiovascular contraindications: Gepants and lasmiditan have no vascular contraindications, unlike triptans and ergots 4
Cost Considerations
The 2025 ACP guideline recommends prescribing less costly medications 1. Triptans and NSAIDs are significantly less expensive than gepants, which should factor into decision-making when efficacy is comparable.
Monitoring for New Adverse Effects
If continuing or switching gepants, monitor for:
- Hypertension: New-onset or worsening, most commonly within 7 days of initiation 2
- Raynaud's phenomenon: New-onset or worsening 2
Evidence Quality Note
The 2025 ACP guideline notes that comparative effectiveness data for gepants versus triptan-NSAID combinations shows gepants may have lower likelihood of pain freedom and sustained pain relief 1. This supports the recommendation to use triptan-NSAID combination as the more effective option when ubrogepant fails.